Liveyon is a cord blood product marketer that distributed a batch of cells a couple of years back that led to many patients being hospitalized with infections. Some had sepsis and ended up in the ICU. It was thought at the time that about a dozen patients who had been injected with the Liveyon product […]
Liveyon product hurt many more patients says new CDC study Read More »
When I first learned about the multi-$10 million cord cell clinic deal between Duke and Cryo-Cell I couldn’t believe what I was reading. Duke’s involved in this? The problem: marketing unproven cells for kids Yes, this wasn’t some stem cell clinic operating out of a strip mall seeking to make big money off of injecting
Vice tackles dicey Cryo-Cell Duke mega-million peds clinic plan Read More »
Stem cell clinic firms often come and go rather quickly, but a few like Regenexx have persisted. It’s even become a brand name. I’ve been writing here on The Niche for more than twelve years about stem cell clinics. Regenexx has been around that whole time. Along with its founder Dr. Chris Centeno. Patients have
Fact-checking Regenexx: reviews, data & cost Read More »
The news of the week relates to an interim clinical trial report from gene-editing firm Editas on its CRISPR trial for a form of vision loss. On to that in a minute. What have you been reading the past week? Below, I include our weekly list of recommended reads. However, first I wanted to give
The Niche weekend reads: Editas mess, The Niche updates, papers Read More »
A piece on human tails and how we lost them caught my eye so I’ll start my weekly reads with that. This week I had the fewest Zoom meetings in ages, which allowed me to get more work done in my own lab and more reading. How about that? I even had some in-person meetings
Recommended reads: a tale of human tails, heart reprogramming, pericytes, microglia Read More »
I’ve been following the research related to human cloning now for more than a decade. Is human cloning more possible at this point? How do we even define such cloning? Did you know there are two types? The goal of this post is to educate you and in the process answer such questions. What’s in
Human cloning is more likely now but would you take the big risks? Read More »
I love stem cell research but experiments that have practical possible future applications in medicine like for vision loss are especially interesting to me. On the other hand basic research on core transcription factor mechanisms like by MyoD also really grab me. We cover some of this stuff and other ground in today’s recommended reads.
Weekly reads: vision, MyoD, liver regen, more Read More »
I’m taking a short break today from working on a big grant to put out this weekly reads post including on Sox transcription factors, cord blood paper controversy, and other interesting papers such as one on CTCF and chromatin domains after mitosis that really struck me. I can actually see blue sky today here in
Weekly reads: CTCF, Sox transcription factors, Clinic fires back, more Read More »
I recently found concerning SEC filings from the biotech Cryo-Cell about a deal it has with a Duke team for infusions of children with unproven umbilical cord cells. This turns out to be a $58 million deal. It relates in a major way to a Duke compassionate use or expanded access program (EAP) that already had raised
FDA should freeze Duke EAP & probe $58 million Cryo-Cell deal linked to it Read More »
It’s been a little quiet here on The Niche for the past week as I was off in Yellowstone National Park, but I’m back with this week’s recommended weekly reads including a section on organoids. First, I want to share a nature pic from the trip. A highlight was encountering a badger in Lamar Valley
Weekly reads: badgers, organoids, The Onion, & more Read More »